Lmy-922
Phase 1
Lmy-922 is one of 34 therapeutic programs targeting Rheumatoid Arthritis (RA). It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
33
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
34 competitors in Non-Hodgkin Lymphoma
#DrugCompanyPhaseTrials
1Rituxan
RochePhase 3
Actemra
RochePhase 3
Polivy
RochePhase 3
LUNSUMIO
RochePhase 3
Epkinly
GenmabPhase 2
Adriamycin
PfizerPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 2
Imbruvica
PPharmacyclics LLC.
Phase 2
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Lmy-922. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 1[1]
- Company
- LLuminary Therapeutics